Trial Profile
Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Apr 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Olaparib (Primary) ; Paclitaxel (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- Acronyms GC-MEDIOLAPAC
- 10 Apr 2023 Planned End Date changed from 30 Apr 2022 to 31 Dec 2023.
- 10 Apr 2023 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2023.
- 21 Jan 2023 Results assessing biomarker oriented analysis to evaluate paclitaxel, olaparib, and durvalumab combination in patients with advanced gastric cancer presented at the 2023 Gastrointestinal Cancers Symposium